Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Extension Study of Seralutinib in PAH
NCT06274801Phase 3Recruiting
- Sponsor
- Gossamer Bio
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 30
01
Overview
A Phase 3 trial of seralutinib in pulmonary arterial hypertension (PAH), sponsored by Gossamer Bio. Started Sep 2024; status: recruiting.
02
Drugs
seralutinib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT06274801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06274801.